A randomized clinical trial reported in the current issue of the Journal of the American Medical Association found that Titan Pharmaceuticals’ (NASDAQ:TTNP) six-month buprenorphine implant, known as Probuphine, may be an effective relapse prevention treatment for stable opioid-dependent adults maintaining clinical stability with 8 mg/d or less of sublingual buprenorphine.
In the double-blind, double-dummy randomized clinical trial, with 177 subjects, the proportion of responders (≥4 of 6 months without illicit opioid use) was 96.4% with buprenorphine implants, compared with 87.6% with sublingual buprenorphine, demonstrating statistical non-inferiority.
The JAMA article can be accessed here.
